The company, which largely remains in stealth mode, has set itself a mission of increasing the human lifespan by a decade.
Retro Biosciences, a US-based company focused on the cellular drivers of aging, has emerged with $180m in funding from undisclosed investors.
The company was co-founded by Sheng Ding, who holds appointments at Gladstone Institutes, University of California (UC), San Francisco, Tsinghua University and Global Health Drug Discovery Institute.
Retro remains in stealth mode – it made its launch announcement on Twitter rather than through a traditional press release – but its website notes that it will aim to increase…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
